Genelux prices $27.5M offering of 6.875M shares and warrants at $4.00

GENELUX Corp

Gross proceeds ~$27.5M; net ~$25.4M from 6,875,000 shares and 6,875,000 warrants at combined $4.00/unit.
Each warrant exercisable at $5.25, immediately exercisable, expires 5 years from issuance.
Underwriters granted 30-day option for additional 1,031,250 shares and warrants (15% over-allotment).
Proceeds to fund working capital into Q1 2026 and Olvi-Vec development; Phase 3 OnPrime topline expected H2 2025.
Closing expected May 29, 2024; Guggenheim Securities sole bookrunner, Newbridge Securities co-manager.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.